These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 1748144)

  • 1. Plasma level monitoring of mitotane (o,p'-DDD) and its metabolite (o,p'-DDE) during long-term treatment of Cushing's disease with low doses.
    Benecke R; Keller E; Vetter B; de Zeeuw RA
    Eur J Clin Pharmacol; 1991; 41(3):259-61. PubMed ID: 1748144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effects of o,p'-DDD on human adrenal steroid synthesis].
    Ojima M; Saito M; Fukuchi S
    Nihon Naibunpi Gakkai Zasshi; 1984 Jul; 60(7):852-71. PubMed ID: 6094274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: results of a long-term follow-up.
    Kasperlik-Zaluska AA; Cichocki A
    J Exp Ther Oncol; 2005; 5(2):125-32. PubMed ID: 16471038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of o,p'-DDD on pituitary-gonadal function in patients with Cushing's disease].
    Ojima M; Hashimoto S; Itoh N; Kusano Y; Satoh K; Egawa M; Gomibuchi T; Fukuchi S
    Nihon Naibunpi Gakkai Zasshi; 1988 Jun; 64(6):451-62. PubMed ID: 3145221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of Cushing's disease with o,p'-DDD followed by pituitary irradiation in a 19-year-old male patient.
    Dickerman Z; Kaufman H; Laron Z
    Isr J Med Sci; 1979 May; 15(5):455-9. PubMed ID: 447515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The long-term therapy of hypothalamic-hypophyseal Cushing's syndrome with mitotane (o,p'-DDD)].
    Knappe G; Gerl H; Ventz M; Rohde W
    Dtsch Med Wochenschr; 1997 Jul; 122(28-29):882-6. PubMed ID: 9264918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. o,p'-DDD (mitotane) treatment for Cushing's syndrome: adrenal drug concentration and inhibition in vitro of steroid synthesis.
    Touitou Y; Moolenaar AJ; Bogdan A; Auzéby A; Luton JP
    Eur J Clin Pharmacol; 1985; 29(4):483-7. PubMed ID: 4092727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significant regression of the tumor combined with the high level of plasma cortisol by low-dose administration of O, p'-DDD in a case with Cushing's syndrome caused by adrenocortical carcinoma.
    Otokida K; Nakamura M; Takeda M; Ito T; Kato M; Masuda T; Tashiro A
    Tohoku J Exp Med; 1986 Dec; 150(4):407-15. PubMed ID: 3564003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of o,p'-DDD on cortisol metabolism in Cushing's syndrome of various etiology.
    Koide Y; Inoue S; Murayama H; Kawai K; Yamashita K
    Endocrinol Jpn; 1985 Oct; 32(5):615-24. PubMed ID: 3004927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood levels of o,p'-DDD following administration in various vehicles after a single dose and during long-term treatment.
    Moolenaar AJ; van Slooten H; van Seters AP; Smeenk D
    Cancer Chemother Pharmacol; 1981; 7(1):51-4. PubMed ID: 7340988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of the adrenocorticolytic compounds 3-methylsulphonyl-DDE and o,p'-DDD (mitotane) in Minipigs.
    Hermansson V; Cantillana T; Hovander L; Bergman A; Ljungvall K; Magnusson U; Törneke K; Brandt I
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):267-74. PubMed ID: 17431626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid micromethod for the analysis of mitotane and its metabolite in plasma by gas chromatography with electron-capture detection.
    Benecke R; Vetter B; De Zeeuw RA
    J Chromatogr; 1987 Jul; 417(2):287-94. PubMed ID: 3654882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of mitotane (o,p-DDD) and its metabolites o,p-DDA and o,p-DDE in plasma by high-performance liquid chromatography.
    Andersen A; Kasperlik-Zaluska AA; Warren DJ
    Ther Drug Monit; 1999 Jun; 21(3):355-9. PubMed ID: 10365653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of o,p'-DDD on plasma ACTH concentration in Cushing's disease.
    Bruno OD; Hoschoian JC; Andrada JA
    Medicina (B Aires); 1979; 39(2):229-34. PubMed ID: 228150
    [No Abstract]   [Full Text] [Related]  

  • 15. The protracted effect of o,p'-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo.
    Leiba S; Weinstein R; Shindel B; Lapidot M; Stern E; Levavi H; Rusecki Y; Abramovici A
    Ann Endocrinol (Paris); 1989; 50(1):49-53. PubMed ID: 2729882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy of the adrenocortical carcinoma with Lysodren (o,p'-DDD). Therapeutic management by monitoring o,p'-DDD blood levels].
    Heilmann P; Wagner P; Nawroth PP; Ziegler R
    Med Klin (Munich); 2001 Jul; 96(7):371-7. PubMed ID: 11494911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of GC/MS/SIM for rapid determination of plasma levels of o,p'-DDD, o,p'-DDE and o,p'-DDA.
    Inouye M; Mio T; Sumino K
    Clin Chim Acta; 1987 Dec; 170(2-3):305-14. PubMed ID: 3436064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement.
    Hogan TF; Citrin DL; Johnson BM; Nakamura S; Davis TE; Borden EC
    Cancer; 1978 Nov; 42(5):2177-81. PubMed ID: 719602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A high-pressure liquid chromatographic method for measuring mitotane [1,1-(o,p'-Dichlorodiphenyl)-2,2-dichloroethane] and its metabolite 1,1-(o,p'-Dichlorodiphenyl)-2,2-dichloroethene in plasma.
    Andersen A; Warren DJ; Nome O; Vesterhus L; Slørdal L
    Ther Drug Monit; 1995 Oct; 17(5):526-31. PubMed ID: 8585118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma.
    Cusato J; De Francia S; Allegra S; Carrella S; Pirro E; Piccione FM; De Martino F; Ferrero A; Daffara FC; Terzolo M; Berruti A; Di Carlo F; Tampellini M; D'Avolio A
    J Pharm Pharmacol; 2017 Nov; 69(11):1524-1530. PubMed ID: 28809444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.